Brand Murray Fuller is a small full-service IP law firm assisting counsel and in-house R&D directly with strong commercial understanding and a common-sense, practical approach. We are a progressive and developing firm, based in central London.
The structure of Brand Murray Fuller was devised differently from the traditional IP firm from the outset. Our staff operate in a highly interconnected fashion, supporting each other beyond their core functions. Attorneys will also be trained to understand fully the support functions necessary to allow the firm to run effectively, consequently gaining business management understanding alongside professional training and development.
We are an environmentally conscious paperless office, which aims to cut out needless printing and filing. Using a vpn-based records system, we reduce our waste and are able to work remotely. Our employees tend to work from home up to twice a week (and as often as necessary when the circumstances dictate), something that is encouraged to maintain a good work/life balance.
Training will involve working with our senior attorneys and attending qualification courses, plus internal and external seminars and tutorials. We believe the best way to learn is through understanding the client and their business, and to that end trainees will attend client meetings and hearings from the start. There are excellent long-term prospects for assisting in the future development and expansion of this new firm.
Our clients range from multinationals with head offices in the UK and US to smaller UK based companies and overseas law firms. We are frequently asked by our clients to advise in connection with wider commercial issues such as agreements, acquisitions, toll manufacturing and trade secrets. Although a young firm, the majority of our attorney-client relationships are long established at a personal level.
While we work on a wide variety of technology, the firm is primarily oriented around the chemical, biotechnology, medtech, green technology, materials, mechanical and pharmaceutical sectors.